Clovis Oncology 미래 성장

Future 기준 확인 0/6

현재 Clovis Oncology 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장	28.3%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Clovis Oncology rises on clinical supply agreement with Isotopia

Sep 21

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Sep 12

Clovis Oncology: Needs Some Encouraging Data Quickly

Aug 11

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Aug 10

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Feb 24

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

Jan 11

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Dec 30

Clovis Oncology Stock: Only Glimmers Of Hope

Oct 07

Clovis: Compelling With Upcoming Catalysts

Jul 30

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Jun 17

Clovis Oncology and Inovio gain amid Reddit chatter

Jun 09

Clovis Oncology: Another Upcycle Coming

May 08

Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds

May 05

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Mar 17

How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Feb 22

Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan

Jan 31

Clovis Oncology: Finally Green Shoots May Be On The Horizon

Jan 29

Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M

Jan 11

What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Dec 31

Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial

Dec 29

Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study

Dec 21

Clovis Oncology existing holder purchases additional $7.5M convertible senior notes

Nov 25

Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance

Nov 09

Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term

Nov 06

Clovis Oncology EPS beats by $0.11, misses on revenue

Nov 05

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Clovis Oncology 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

OTCPK:CLVS.Q - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
9/30/2022	133	-252	-176	-176	N/A
6/30/2022	140	-263	-181	-181	N/A
3/31/2022	145	-258	-193	-193	N/A
12/31/2021	149	-265	-196	-196	N/A
9/30/2021	156	-299	-211	-211	N/A
6/30/2021	157	-310	-219	-219	N/A
3/31/2021	160	-336	-241	-232	N/A
12/31/2020	165	-369	-261	-253	N/A
9/30/2020	161	-370	-275	-267	N/A
6/30/2020	159	-385	-279	-269	N/A
3/31/2020	152	-413	-311	-308	N/A
12/31/2019	143	-400	-343	-324	N/A
9/30/2019	134	-400	-356	-336	N/A
6/30/2019	119	-396	-376	-352	N/A
3/31/2019	110	-377	-444	-364	N/A
12/31/2018	95	-368	-430	-366	N/A
9/30/2018	82	-321	-412	-349	N/A
6/30/2018	76	-291	-380	-322	N/A
3/31/2018	67	-366	-282	-281	N/A
12/31/2017	56	-346	-265	-261	N/A
9/30/2017	39	-365	-254	-250	N/A
6/30/2017	22	-370	-268	-265	N/A
3/31/2017	7	-324	-267	-263	N/A
12/31/2016	0	-349	-267	-267	N/A
9/30/2016	N/A	-398	-290	-288	N/A
6/30/2016	N/A	-431	N/A	-299	N/A
3/31/2016	N/A	-373	N/A	-288	N/A
12/31/2015	N/A	-353	N/A	-253	N/A
9/30/2015	N/A	-288	N/A	-211	N/A
6/30/2015	N/A	-229	N/A	-174	N/A
3/31/2015	N/A	-192	N/A	-146	N/A
12/31/2014	14	-160	N/A	-117	N/A
9/30/2014	14	-134	N/A	-107	N/A
6/30/2014	14	-115	N/A	-88	N/A
3/31/2014	14	-100	N/A	-77	N/A
12/31/2013	N/A	-85	N/A	-72	N/A
9/30/2013	N/A	-76	N/A	-67	N/A
6/30/2013	N/A	-74	N/A	-65	N/A
3/31/2013	N/A	-71	N/A	-61	N/A
12/31/2012	N/A	-74	N/A	-65	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CLVS.Q 의 예상 수익 증가율이 절약률( 2.1% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: CLVS.Q 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: CLVS.Q 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: CLVS.Q 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: CLVS.Q 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CLVS.Q 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Clovis Oncology 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Consensus revenue estimates fall by 13%

Consensus revenue estimates fall by 18%

Price target increased to US$6.33

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Price target increased to US$6.33

Price target increased to US$6.38

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology rises on clinical supply agreement with Isotopia

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Consensus revenue estimates fall by 13%

Clovis Oncology: Needs Some Encouraging Data Quickly

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Clovis Oncology Q2 2022 Earnings Preview

EMA recommends restricted use of Clovis cancer drug

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology climbs 34% as shareholders reject reverse stock split

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Clovis: Shifting Toward Nuclear Medicine

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Clovis Oncology: Forging A Fresh Perspective

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: EPS exceeds analyst expectations

Consensus revenue estimates fall by 18%

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Price target increased to US$6.33

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Price target increased to US$6.33

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Price target increased to US$6.38

Clovis Oncology Stock: Only Glimmers Of Hope

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Price target decreased to US$5.90

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis: Compelling With Upcoming Catalysts

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Clovis Oncology and Inovio gain amid Reddit chatter

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

Clovis Oncology: Another Upcycle Coming

Consensus forecasts updated

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Price target decreased to US$6.35

Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Insider recently sold US$56k worth of stock

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Revenue and earnings beat expectations

How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: US$9.36

Executive VP exercised options and sold US$95k worth of stock

Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan

Clovis Oncology: Finally Green Shoots May Be On The Horizon

New 90-day high: US$6.12

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021